| Name | Title | Contact Details |
|---|
Ashwood Retirement & Assisted is a Austin, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Joint Commission Resources is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
VetEvolve offers relationship-focused veterinary practice acquisition that helps you put the focus back on your patients with our superior business management.
Since 1983, Schulman has provided the research community with IRB review services of the highest quality. In establishing the IRB, our founders sought to promote clinical research by helping to safeguard the rights and welfare of clinical research subjects. Schulman’s team of dedicated professionals seeks to provide timely, quality services based on the foundation of respect for persons, beneficence and justice. Through continuous quality improvement and rigorous training on human subject protection, Schulman provides thorough, ethical, responsive and thoughtful review of research studies. By combining impeccable review standards, savvy industry insight, responsive customer service and innovative technological solutions, Schulman creates a review experience that goes beyond the expected. We look forward to continued collaboration with our colleagues in North America and around the world as we uphold our mission to protect the rights and welfare of clinical research subjects.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.